Statins Do Double Duty Against Stroke

Slideshow

A new study suggests that inpatient statin use is linked to improved outcomes after intracranial hemorrhage. And 2 new studies suggest that a new class of injectable antihyperlipidemics, the PSK9 inhibitors--which have been shown to lower LDL-- may decrease cardiovascular events, including stroke.Details of those studies appear in the following slides. Take home points include:Inpatient statin use is linked to improved outcomes after ICH, and that stopping statins during hospitalization is associated with worse outcomes.PSK9 inhibitors are a new class of injectable antihyperlipidemics that have been shown to lower LDL and may also decrease risk of cardiovascular events, including strokeA study has suggested that evolocumab, a new PSK9 inhibitor, plus standard therapy reduces LDL by 61% and cardiovascular events by about half, compared to standard therapy aloneAnother study has suggested that  alirocumab, also a PSK9 inhibitor, reduces LDL by 62% and cardiovascular risk by about half, compared to placeboBoth PSK9 inhibitors were linked to increased rates of neurocognitive disorders

Related Videos
Ashkan Shoamanesh, MD
Opeolu Adeoye, MD, MS; Andrew Barerrto, MD, MS
David Z. Rose, MD
Shadi Yaghi, MD, associate professor of neurology at Brown University
Ava L. Liberman, MD, medical director of the Stroke Center at Weill Cornell Medicine
© 2024 MJH Life Sciences

All rights reserved.